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ABSTRACT 
 
Renal cell carcinoma (RCC) is a heterogeneous group of kidney cancers with clear 
cell RCC (ccRCC) as the major subgroup. To expand the number of clinically-
relevant tumor-associated antigens (TAAs) that can be targeted by immunotherapy, 
we analyzed samples from 23 patients with primary ccRCC for the expression and 
immunogenicity of various TAAs. We found high frequency expression of MAGE-A9 
and NY-ESO-1, in 36% and 55% of samples, respectively, and overexpression of 
PRAME, RAGE-1, CA-IX, Cyclin D1, ADFP, C-MET and RGS-5 in many of the tumor 
samples. We analyzed the blood of HLA-A2+ ccRCC patients for the presence of 
CD8+ T cells specific for TAA-derived HLA-A2-restricted peptides and found 
spontaneous responses to Cyclin D1 in 5 of 6 patients with Cyclin D1-positive 
tumors. Cyclin D1-specific CD8+ T cells secreted TNF-α, IFN-γ, and IL-2, and 
degranulated, indicating the presence of polyfunctional tumor-specific CD8+ T cells in 
the blood of these ccRCC patients. The high frequency (43%) of Cyclin D1 
overexpression and the presence of functional Cyclin D1-specific T cells in 83% of 
these ccRCC patients suggest that Cyclin D1 may be a target for immunotherapeutic 
strategies. 
 
 
INTRODUCTION 
 
The immune system recognizes and controls tumors through a process called cancer 
immune surveillance (1). Studies showed a correlation between tumor infiltration by T 
cells and patient survival in various cancers (2). Furthermore, spontaneous immunity 
against tumor-associated antigens (TAAs) can be detected in cancer patients (3) . 
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TAAs include cancer-testis (CT) antigens, differentiation antigens, mutated proteins, 
overexpressed proteins and viral antigens (4). Boosting spontaneous TAA-specific 
immunity is a low toxicity strategy, which resulted in objective clinical responses in 
some cancer patients (5).  
Renal cell carcinoma (RCC) is a heterogeneous cancer that encompasses about 
90% of all human kidney tumors and clear cell RCC (ccRCC) is the major histological 
subgroup (6). About one-third of RCC have already metastasized at the time of 
diagnosis, and 20-50% of resected patients develop metastasis (7). Treatment of 
advanced and metastatic RCC is challenging due to its relative resistance to 
chemotherapy and radiotherapy (8). 
Evidence supporting RCC as an immunogenic cancer includes cases of spontaneous 
regressions, increased incidence in immunosuppressed patients, and the high 
density of tumor-infiltrating leukocytes (TILs) (9). Since the 1980s, immunostimulatory 
compounds such as IL-2 and IFN-α are being used to treat RCC. Despite modest 
therapeutic efficacy in some patients, the concomitant severe systemic toxicity 
remains a problem (8). Furthermore, data showing TAA-specific immunity in RCC 
patients are scarce.  
We performed qRT-PCR on  samples from 23 patients with primary ccRCC for the 
expression of genes encoding CT antigens MAGE -A1 (CT1.1), -A3 (CT1.3), -A4 
(CT1.4), -A9 (CT1.9), -A10 (CT1.10), synovial sarcoma X breakpoint 2 
(SSX2/CT5.2), New York esophageal I (NY-ESO-1/CT6.1), L antigen 1 (LAGE-
1/CT6.2) and MAGE-C1 (CT7), carbonic anhydrase IX (CA-IX/G250), renal antigen 1 
(RAGE-1), preferentially expressed antigen of melanoma (PRAME), adipose 
differentiation-related protein (adipophilin/ADFP), C-MET proto-oncogene, Cyclin D1 
(CCND1), and regulator of G-protein signaling 5 (RGS-5). We also determined 
whether spontaneous T cell responses were elicited against any of these antigens. 
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MATERIALS AND METHODS 
 
Patients 
Patients with ccRCC underwent full or partial nephrectomy as part of their standard 
treatment at the Department of Urology, University Hospital Zurich, between 2008 
and 2011. Tumor specimens and peripheral whole blood were obtained following 
informed consent in accordance with the Declaration of Helsinki. The local ethics 
committee approved the study (EK-1017, EK-1634). Detailed patients’ characteristics 
are listed in Table 1. All patients were HLA-A2-typed using FITC-conjugated HLA-A2-
specific or isotype control antibodies (BioLegend), on a CyAn ADP 9 flow cytometer 
(Beckman Coulter), and data were analyzed using FlowJo software (TreeStar).  
 
Processing of blood and tumor samples 
PBMCs were isolated from peripheral blood by Ficoll (Ficoll-PaqueTM PLUS; GE 
Healthcare) density centrifugation. Immediately after surgery a small piece of tumor 
tissue was snap-frozen in liquid nitrogen for RNA isolation. The remaining tumor was 
digested with 6 U/mL DNase I Type IV (Sigma), 1 mg/mL collagenase IV (Sigma) in 
DMEM (Gibco), 50 U/mL penicillin, and 50 U/mL streptomycin (Gibco) for 1–2 h at 
37°C. The resulting single-cell suspensions and the PBMCs were cryopreserved at -
80°C until analysis. 
RNA isolation 
Total RNA was extracted from snap-frozen ccRCC tumor samples using the RNeasy 
Mini Kit (Qiagen) followed by digestion with DNase I (New England BioLabs) 
according to manufacturer’s instructions. 
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Real-time quantitative reverse transcription-polymerase chain reaction (qRT-
PCR) 
The concentration and purity of RNA were evaluated using the NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies). 500 ng of RNA was reverse 
transcribed using the high-capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) according to manufacturer’s instructions; cDNA was stored at -20 °C 
until qRT-PCR analysis performed on a Rotor-Gene Q real-time PCR cycler (Qiagen) 
using commercially available TaqMan reagents with optimized primer and probe 
concentrations (TaqMan® gene expression assays, Applied Biosystems) (Table 2). 
After an initial hold for 2 min at 50 °C and 10 min at 95 °C the probes were cycled 45 
times at 95 °C for 15 sec and at 60 °C for 60 sec. All PCR reactions were performed 
in triplicates. Threshold cycle (Ct) values were determined with the Rotor-Gene Q 
Series software 1.7. ΔCt values were calculated by normalizing the target mRNA 
levels to the endogenous control 18s-rRNA (Hs03928990_g1, Applied Biosystems). 
Testis cDNA generated from human testes total RNA (Invitrogen), served as positive 
control for expression analysis of CT antigens. As qRT-PCR for MAGE-A9 suggested 
low expression in the healthy kidney control (CT 35, ΔCT 30), expression in ccRCC 
specimens was considered positive at a CT < 35 and a ΔCt < 30. For overexpressed 
antigens ΔCt levels of tumors were compared to ΔCt levels of healthy kidney control 
(human kidney total RNA, Invitrogen) using the 2-ΔΔCt formula. Only changes ≥ 2 fold 
were considered as overexpression.  
 
Genomic DNA extraction 
Punch biopsies from paraffin-embedded ccRCC samples were incubated (10 min at 
95 ºC) with 300 μL of buffer containing 20 mM Tris pH 8.0, 20 mM EDTA and 1% 
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SDS. After cooling down, 3 μL of Proteinase K (18 +/- 4 mg/mL, Roche) were added 
to each sample and incubated at 55 ºC for 72 hours. Digested samples were 
centrifuged and 4 volumes of RLT buffer (AllPrep DNA/RNA Mini Kit, Qiagen) was 
added to the supernatant. Genomic DNA was extracted following manufacturer’s 
protocol.  
 
Cyclin D1 sequencing 
Purified genomic DNA was amplified using the Phusion Hot Start High-Fidelity DNA 
Polymerase (Finnzymes) with the following PCR conditions: 10 min at 98 °C, 
followed by 34 cycles of 30 sec at 98 ºC, 30 sec at 68 ºC, 20 sec at 72 ºC with a final 
elongation of 5 min at 72 ºC. Sequences encoding the HLA-A2-restricted 
CTL epitope corresponding to Cyclin D1 amino acids 101-109 or 228-236 were 
amplified using forward primer 5’-TGCGAGGAACAGAAGTGCGA-3’ / reverse primer 
5’-TCCAGTGGTTACCAGCAGCTC-3’ or forward primer 5’-
TGCTCACAGCCTCCTTCCCT-3’ / reverse primer 5’-TCGGCATTTCCGTGGCACTA-
3’ respectively. PCR products were purified using QIAquick Gel Extraction Kit 
(Qiagen) and sequenced using the same amplification primers. 
 
 
 
MACS sorting and in vitro stimulation 
T cell stimulation was performed as described (10). Briefly, CD8+ and CD4+ T cells 
were isolated sequentially from PBMCs by positive selection using MACS (Miltenyi 
Biotech) according to manufacturer’s instructions. The remaining CD8-CD4- fraction 
was used as antigen presenting cells (APCs), which were loaded with 10-5 M of each 
peptide (Table 2). For in vitro stimulation 5 × 105 CD8+ T cells were incubated with 5 
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× 105 loaded and irradiated (30 Gy) APCs in 96-well flat bottom plates. Cells were 
cultured for 9 days in 200 μL TC-RPMI (i.e. RPMI (Gibco), supplemented with 
NaHCO3 (2 g/L, Sigma), L-glutamine (2 mM, Sigma), penicillin and streptomycin (50 
U/mL, Gibco), MEM nonessential amino acids (1X, Gibco), sodiumpyruvate (1 mM, 
Gibco), 10−4 M β-mercaptoethanol (Sigma) and 10% pooled human serum) plus 
DNase I (6 U/mL, Sigma)). T-APCs were generated from purified autologous CD4+ T 
cells stimulated with 1 μg/mL phytohemagglutinin (PHA, Sigma) and 100 U/mL 
recombinant IL-2 (R&D Systems) during the 9-day culture. T-APCs were used as 
APCs during the short in vitro stimulation before intracellular cytokine staining. Media 
was exchanged every second day with TC-RPMI containing 25 U/mL IL-2. 
 
Intracellular cytokine staining (ICS) 
At day 9, the presence of TAA-specific T cells was tested by short-term restimulation 
with relevant peptides, followed by ICS. Briefly, T cells were stimulated with peptide-
loaded autologous T-APCs at a 1:2 ratio for 5 h in the presence of Brefeldin A 
(10 µg/mL, Sigma), monensin (10 µg/mL, Sigma), 1 μg/mL anti-CD28/49d (BD) and 
appropriately diluted phycoerythrin (PE)-labeled anti-CD107a antibody. Before 
addition to the assay T-APCs were labeled with 2 µM carboxyfluoresceinsuccinimidyl 
ester (CFSE, Sigma), which allowed their exclusion before analysis. Surface staining 
for CD45-PerCP, CD3-Pacific Orange (Invitrogen), CD8-ECD (Beckman Coulter), 
CD14-FITC, CD16-FITC, CD19-FITC, and live-dead staining (LIVE/DEAD® Fixable 
Green Dead Cell Stain Kit, Invitrogen) was performed in PBS (NaCl (136mM, Fluka), 
Na2HPO4 (8mM, Roth), KH2PO4 (1.5mM, Roth), pH 7) for 20 min at room 
temperature. Subsequently, cells were fixed with 4% formalin (Kantonsapotheke 
Zurich) and incubated for 5 min at RT with permeabilization buffer (PB: PBS 
supplemented with 2mM EDTA (Sigma), 2% FCS (PAA Laboratories), 0.05% NaN3 
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(Sigma) and 0.1% Saponin (Sigma)). Intracellular staining was performed using IFN-
γ-APC, TNF-α-PECy7 (ebiosciences) and IL-2-Pacific Blue antibodies in PB for 
20 min at room temperature in the dark. Cells were washed once with PB and 
resuspended in PBS containing 1% formalin. Samples were evaluated by flow 
cytometry and data analyzed with FlowJo software as described earlier. Unless 
stated differently, all antibodies were purchased from BioLegend. 
 
Tetramer Staining 
PBMCs or digested tumor samples were stained with tetramers for the presence of 
TAA-specific CD8+ T cells. Briefly, cells were resuspended in PBS and incubated for 
10 min at 37°C with PE-labeled tetramers consisting of HLA-A2 plus Cyclin D1101-109, 
Cyclin D1228-236, CMV495-503 or FLU-MATRIX58-66, followed by incubation with anti-
CD45 APC, anti-CD8 Pacific Blue (both BioLegend) and live-dead stain 
(LIVE/DEAD® Fixable Aqua Dead Cell Stain Kit, Invitrogen) for 15 minutes at 4°C. 
Cells were washed once with PBS and resuspended in PBS containing 1% formalin. 
Samples were evaluated by flow cytometry and data analyzed with FlowJo software. 
The percentage of tetramer-positive cells was determined after gating on live, CD45+ 
CD8+ cells. 
Western Blotting 
The presence of Cyclin D1-specific IgG in patient sera was tested by western blotting 
as described (11) using recombinant human Cyclin D1 (AbnovaCat.No. H00000595-
PO1). Sera from 22 ccRCC patients were used at a 1:250 dilution. MaxPab mouse 
polyclonal anti-human CCND1 (AbnovaCat.No. H00000595-BO1P) was used as 
positive control at 1:1000 dilution. HRP-conjugated goat anti-mouse IgG (Jackson 
115-035-008) was used as positive control and HRP-conjugated goat anti-human IgG 
(Jackson 109-035-006) for serum samples at a dilution of 1:25,000. Blots were 
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developed with Western Lightning Plus ECL reagents (Perkin Elmer Cat.No. 
NEL104001EA) and signals were measured using a Fusion FX7 machine (VILBER 
LOURMAT). 
 
 
RESULTS 
 
Frequent expression of tumor-associated antigens in primary ccRCC tumor 
samples 
The expression of 9 CT and 7 other antigens in 23 primary ccRCC specimens was 
analyzed by qRT-PCR. We found expression of MAGE-A9 and NY-ESO-1 in 36% 
and 55% of samples, respectively, and did not find expression of the other 7 CT 
antigens in any samples (Figure 1A). Although MAGE-A9 and NY-ESO-1 were 
frequently expressed, their expression levels were very low (Figure 1B). 
Overexpression of RAGE-1 in 13%, C-MET in 30%, PRAME in 39%, Cyclin D1 in 
43%, ADFP in 65%, RGS-5 in 83%, and CA-IX in 96% of ccRCCs specimens was 
also obserbed (Figure 1A, B). More than 50% of the ccRCC specimens co-
expressed 4-6 different TAAs (Figure 1C). We found no evidence for preferred co-
expression of particular TAAs (Figure 1D). 
Spontaneous Cyclin D1-specific CD8+ T cell responses in patients with primary 
ccRCC 
Because of limited specimen availability, we selected HLA-A2+ patients and used 
previously described HLA-A2-restricted peptides for stimulation of PBMCs 
(http://www.cancerimmunity.org/CTdatabase (12-14), summarized in Table 2). After 
in vitro culture for 9 days with the relevant peptides, we performed a 5 hr 
restimulation with the same peptides in the presence of brefeldin A and monensin, 
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followed by ICS for effector cytokines TNF-α, IFN-γ and IL-2, and staining for 
degranulation (surface CD107a). We found CD8+ T cells specific for Cyclin D1-
derived peptides in 5 of 6 HLA-A2+ patients, whose tumors overexpressed Cyclin D1 
(Figure 2A), but not for any of the other peptides tested (data not shown). Due to 
limited material, the readout for patient samples Z-H-903, Z-H-209, Z-H-929 and Z-H-
1055 was performed with both Cyclin D1-derived peptides (Cyclin D1101-109 and 
Cyclin D1228-236) together. Since there were enough speimens from patients Z-H-1184 
and Z-H-1257, we analyzed the two Cyclin D1-derived epitopes separately, and 
found that responses in both patients were directed against Cyclin D1101-109 as 
illustrated by representative staining of specimens from patient Z-H-1184 (Figure 
2B). Furthermore, the Cyclin D1-specific CD8+ T cell in all 5 patients were 
polyfunctional although only few cells secreted IL-2 (Figure 2C). To exclude the 
possibility that the Cyclin D1-specific CD8+ T cell responses were due to in vitro 
priming rather than to in vivo induction by Cyclin D1-overexpressing tumors, we 
performed a similar experiment with PBMCs from 3 healthy, HLA-A2+ donors. 
CMV495-503 was used as positive control because these donors were selected by the 
presence of CMV tetramer-specific CD8+ T cells. We did not find Cyclin D1-specific 
CD8+ T cell responses in these healthy donors, whereas CMV-specific CD8+ 
responses were readily detectable by ICS (data not shown). 
To confirm the presence of Cyclin D1-specific T cells we performed ex-vivo tetramer 
staining on PBMCs (Supplementary Figure S1A) and TILs (Supplementary Figure 
S1B) from ccRCC patients, when sufficient material was available. In PBMCs from 
patient Z-H-209, who did not show a Cyclin D1-specific response after in vitro 
stimulation, we also did not detect Cyclin D1 tetramer-positive T cells. However, in 
PBMCs from patients (Z-H-903, Z-H-1055 and Z-H-1184), who responded to in vitro 
Cyclin D1-specific peptide stimulation, we detected Cyclin D1-specific T cells by 
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tetramer staining (Supplementary Figure S1A). While we did not find Cyclin D1 
tetramer-specific T cells in TILs of patient Z-H-929, whose PBMCs responded weakly 
to Cyclin D1-specific peptide stimulation in vitro, we detected Cyclin D-1 tetramer-
specific T cells in TILs of patients Z-H-1184 and Z-H-1257, whose PBMCs  secreted 
cytokines  upon peptide stimulation in vitro (Supplementary Figure S1B). 
To investigate whether Cyclin D1 induced humoral immune response in ccRCC 
patients, particularly those who overexpress Cyclin D1, we tested for Cyclin D1-
specific antibodies by Western blotting, but did not find Cyclin D1-specific antibodies 
in the sera of the 22 patients tested (Supplementary Figure S2). 
 
 
DISCUSSION 
 
To expand the number of clinically-relevant TAAs that can be targeted by 
immunotherapy in patients with RCC, we investigated the expression of 9 CT 
antigens and 7 other antigens (15), in samples from 23 patients diagnosed with 
primary ccRCC. Most tumors expressed more than one TAA, which has been 
described for other tumor entities (16-18), and which enables therapeutic-targeting of 
multiple antigens at the same time. 
Except for MAGE-A9 and NY-ESO-1, we did not detect expression of the other 7 CT 
antigens in our patient cohort. Although two studies showed expression for MAGE-A3 
and -A4 in RCC (19, 20), our results are in line with that described in a previous 
review on CT antigens (21). The expression frequency of MAGE-A9 in RCC is similar 
to that shown by Oehlrich and colleagues (12) however, we found only very low 
levels of MAGE-A9 transcripts. As they have reported (12), we also detected a signal 
for MAGE-A9 in the healthy kidney tissue control. The frequency of NY-ESO-1 
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expression in CCR was unexpected based on immunohistochemistry data published 
over a decade ago (22-24). The discrepancy may be explained by the highly 
sensitive qRT-PCR method we used that allowed the detection of very low levels of 
NY-ESO-1 transcripts. Although RAGE-1 was the first antigen recognized by 
autologous T cells from a human RCC cell line, it was only detected in 1 of 57 RCC 
samples (25). Our results (13%) are in agreement with studies that identified higher 
expression frequencies, which presumably is also due to the more sensitive methods 
used (12, 22). The frequency of PRAME-expression (39%) in ccRCC is in 
accordance with previously published reports (20, 22).  
The von Hippel-Lindau protein (VHL) is mutated in most ccRCC samples leading to 
reduced proteolytic degradation of hypoxia inducible factor α (HIF-α), resulting in 
upregulated HIF-α-mediated transcriptional programs (26). CA-IX is an HIF-α target 
gene that is frequently expressed in RCC but very rarely detected in normal kidney 
tissue (27). We observed an overexpression of CA-IX in all but one ccRCC samples. 
CA-IX has been identified as a therapeutic target for RCC (13, 28, 29), and evaluated 
in clinical studies (30-32), but it has not yet induced strong antitumor immune 
responses. In addition to CA-IX, ADFP, Cyclin D1, C-MET and RGS-5 are also 
overexpressed in ccRCC (14). In contrast to published reports (33, 34), we found 
ADFP expressed more frequently (65%) than C-MET (30%). Cyclin D1 is a cell cycle 
regulator crucial for the G1-S transition (35) and is overexpressed in many cancers 
including colorectal and breast carcinoma (36, 37). We found Cyclin D1 
overexpressed in 43% of the primary ccRCC samples, similar to previous published 
data (38-40).   
Many factors impact the success of immunotherapy (22). Despite the high frequency 
of expression (55%) of NY-ESO-1 in ccRCC samples, which is one of the most 
immunogenic CT antigens (24, 41), we did not find NY-ESO-1-specific CD8+ T cell 
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responses in any of the HLA-A2+ ccRCC patients, which may be explained by the low 
level of NY-ESO-1 expression. ADFP, C-MET and RSG-5 are not immunogenic in 
ccRCC patients, as we did not detect T cell responses specific for these antigens, 
despite their frequent overexpression. This is in agreement with previously published 
data on rare T cell responses in ccRCC patients (15), even though ADFP- and C-
MET-specific T cells could be expanded from the blood of healthy donors (33, 34). 
RGS-5 overexpression did not result in detectable RGS-5-specific T cell responses in 
our cohort, although such responses were reported in blood of healthy donors and 
patients with acute myeloid leukemia (42). In contrast, we detected Cyclin D1-specific 
CD8+ T cells in the blood of 5 of 6 HLA-A2+ ccRCC patients, whose tumors 
overexpressed Cyclin D1. Unlike cyclin-dependent kinase 4 (CDK4) in melanoma 
(43), we did not find mutation in the two Cyclin D1 epitopes in ccRCC (data not 
shown). 
Ex vivo tetramer staining confirmed the presence of Cyclin D1-specific T cells in 
patients who secreted cytokines upon in vitro Cyclin D1-specific peptide stimulation. 
Although we detected a higher frequency of T cells specific for Cyclin D1228-236 by 
tetramer in blood and TILs, we found a higher frequency of T cells specific for Cycllin 
D1101-109 after in vitro restimulation. Since Cyclin D1228-236 is the immunodominant 
peptide, which may induce more extensive in vivo proliferation of specific T cells and 
thus compromising their ability to further expand in vitro. Alternatively, tetramer-
positive T cells may not be functional, suggesting a preferential functional exhaustion 
of T cells specific for Cyclin D1228-236. 
There is no association identified between Cyclin D1 expression and ccRCC 
prognosis (40); although Cyclin D1 overexpression is associated with shorter patient 
survival in other cancers and thus represents an interesting therapeutic target (44). 
However, Cyclin D1 is difficult to target as it is expressed in the cytosol and lacks 
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intrinsic enzymatic activity. One approach is to block its activity indirectly by inhibiting 
associated kinases with kinase inhibitors (45); however, this strategy does not 
interfere with its kinase-independent tumor-promoting effects.  
Cyclin D1 induces T cell responses in mantle cell lymphoma and colon cancer, and 
antibodies in prostate cancer (46-49); and was identified as a target for 
immunotherapy in mantel cell lymphoma (50).  
To our knowledge this is the first study that describes naturally occurring Cyclin D1-
specific CD8+ T cell responses in cancer patients. Importantly, these responses have 
polyfunctional effector characteristics. We therefore propose Cyclin D1 as a target for 
immunotherapy in patients with ccRCC. 
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FIGURE LEGENDS 
 
Figure 1: Expression of TAA transcripts in ccRCC specimens 
RNA was isolated from 23 primary ccRCC samples, reverse transcribed and cDNA 
used as template for qRT-PCR analysis. (A) Frequency of expressed TAAs in 
primary ccRCC samples. (B) Detected ΔCT levels for the different TAA transcripts of 
the individual tumor samples after normalization to the endogenous control 
(18SrRNA). Results from tumor samples are represented as open, from testis as 
filled, and from healthy kidney as half-filled symbols. (C, D) Co-expression of TAAs in 
primary ccRCC samples. 
 
Figure 2: Cyclin D1-specific CD8+ T cell response in PBMCs of ccRCC patients 
CD8+ T cells from PBMCs of HLA-A2+ patients with Cyclin D1-overexpressing tumors 
were stimulated for 9 days with Cyclin D1-derived peptides in the presence of IL-2. 
Restimulation was performed using both Cyclin D1-derived epitopes (Cyclin D1101-109 
and Cyclin D1228-236) together, separately or no peptide as highlighted in the figure, 
followed by surface staining for CD107a and intracellular staining for TNF-α, IFN-γ 
and IL-2. Cytokine production of CD8+ T cells was measured after gating on live 
CD45+, CD3+, CD8+, CD14-, CD16-, CD19- cells. (A) Summary of results from 6 
individual patients. (B) Representative staining (patient Z-H-1184) of single cytokine 
secretion and (C) polyfunctional cytokine response. 
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Table 1 
 
Patient information 
 
          
Histology clear cell renal cell carcinoma 
    
Patient number n=23   
    
Age (years) 37-84 (64.1 ± 11)   
  
Pathological Stage pT1 1   
  pT1a 8
  pT1b 4   
  pT2 3   
  pT3 0   
  pT3a 3   
  pT3b 4   
  pT3c 0   
  pT4 0   
          
 
Table 2 
 
Taq-Man Assays of TAAs and derived HLA-A2-restricted peptides 
 
  TaqMan Assay ID Position Peptide Sequence Peptide Source 
MAGE-A1 Hs00607097_m1 278-286 KVLEYVIKV not used 
MAGE-A3 Hs00366532_m1 271-279 FLWGPRALVd not used 
MAGE-A4 Hs00365979_m1 230-239 GVYDGREHTV not used 
MAGE-A9 Hs00893224_m1 223-231 ALSVMGVYV Thermo Scientific 
MAGE-A10 Hs01560792_m1 254-262 GLYDGMEHL not used 
SSX2 Hs00817683_m1 41-49 KASEKIFYV not used 
NY-ESO-1 Hs00265824_m1 157-165 SLLMWITQC Bio Synthesis 
LAGE-1 Hs00535628_m1 41214 MLMAQEALAFL not used 
    157-165 SLLMWITQV not used 
MAGE-C1 Hs00193821_m1 959–968  ILFGISLREV not used 
    1083–1091 KVVEFLAML not used 
PRAME Hs00196132_m1 425-433 SLLQHLIGL Thermo Scientific 
    100-108 VLDGLDVLL Thermo Scientific 
RAGE-1 Hs00179504_m1 32-40 PLPPARNGGL Thermo Scientific 
    352-360 LKLSGVVRL Thermo Scientific 
CA-IX Hs00154208_m1 254-262 HLSTAFARV Thermo Scientific 
CCND1 Hs00765553_m1 101-109 LLGATCMFV  S. Stefanovic, Tuebingen 
    228-236 RLTRFLSRV  S. Stefanovic, Tuebingen 
ADFP Hs00765634_m1 129-137 SVASTITGV  S. Stefanovic, Tuebingen 
C-MET Hs00179845_m1 654-662 YVDPVITSI  S. Stefanovic, Tuebingen 
RGS-5 Hs00186212_m1 5-13 LAALPHSCL  S. Stefanovic, Tuebingen 
 


